About Allos Therapeutics
Allos Therapeutics is a Healthcare company based in Denver (United States) founded in 1992, and was acquired by Spectrum Pharmaceuticals in April 2012. US-based, commercial stage biopharma commercializing a folate analog for Non-Hodgkins Lymphoma. Its chief executive, as recorded, is Paul L Berns. Allos Therapeutics offers products and services including Causal AI. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Allos Therapeutics, Inc. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Allos Therapeutics (formerly HemoTech Sciences) US-based, commercial stage biopharma commercializing a folate analog for Non-Hodgkins Lymphoma. It focuses on the development and commercialization of Folotyn (pralatrexate injection), a folate analog metabolic inhibitor. Folotyn is approved in the US for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Allos reported making 20.7 million in revenue from Folotyn sales in the first six months of 2012 (it made 21.8 million in the first six months of 2011). It is also developing Folotyn in other hematologic malignancies. As of September 2012, Allos Therapeutics operates as a subsidiary of Spectrum Pharmaceuticals.
- Headquarters Denver, United States
- Stage Acquired
- SectorsHealthcare
- Website allos.com
- Social LinkedIn
- Acquired by Spectrum Pharmaceuticals (Apr 2012)
- Legal Name Allos Therapeutics, Inc.
- Investors
- Acquired bySpectrum Pharmaceuticals
(Apr 2012)
Products & Services of Allos Therapeutics
Allos Therapeutics offers a comprehensive portfolio of products and services, including Causal AI.
Technology for forecasting clinical intervention effects on patient outcomes.
Investors in Allos Therapeutics
Allos Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Spectrum Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecule therapeutics for oncology and hematology are developed. | 1987 | sppirx.com | Henderson, United States |
Investor details for Allos Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allos Therapeutics
2 people are tracked at Allos Therapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Paul L Berns | CEO | Leadership |
Felice Ginsburg | CEO | Leadership |
Complete people profiles for Allos Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Allos Therapeutics
3 dated milestones of Allos Therapeutics across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Allos Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Spectrum Pharmaceuticals.
Competitors of Allos Therapeutics
Allos Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Allos Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Allos Therapeutics
Websites that share an audience with Allos Therapeutics (allos.com).
Websites whose visitors overlap most with Allos Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| micromet.de | 100% | View details | |||
| acimmune.com | 100% | 11.3K | #1,671,085 | View details | |
biotica.co.uk | biotica.co.uk | 100% | – | ||
crusadelabs.co.uk | crusadelabs.co.uk | 100% | – | ||
topotarget.com | topotarget.com | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Allos Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Allos Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Allos Therapeutics
Complete news archive for Allos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allos Therapeutics
Allos Therapeutics was founded in 1992.
Allos Therapeutics is headquartered in Denver, United States. It is registered at Denver, Colorado, United States.
Paul L Berns is the CEO of Allos Therapeutics, as recorded in our data.
Allos Therapeutics (formerly HemoTech Sciences) US-based, commercial stage biopharma commercializing a folate analog for Non-Hodgkins Lymphoma. It focuses on the development and commercialization of Folotyn (pralatrexate injection), a folate analog metabolic inhibitor. Folotyn is approved in the US for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Allos reported making 20.7 million in revenue from Folotyn sales in the first six months of 2012 (it made 21.8 million in the first six months of 2011). It is also developing Folotyn in other hematologic malignancies. As of September 2012, Allos Therapeutics operates as a subsidiary of Spectrum Pharmaceuticals.
Allos Therapeutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Allos Therapeutics offers Causal AI.
Allos Therapeutics has 1 investor. Key investors include Spectrum Pharmaceuticals.
Allos Therapeutics operates through Allos Therapeutics, Inc..
Yes. Allos Therapeutics was acquired by Spectrum Pharmaceuticals in April 2012.